Published in Histopathology on February 09, 2012
STAT signaling in mammary gland differentiation, cell survival and tumorigenesis. Mol Cell Endocrinol (2013) 1.04
The tumor suppressor function of STAT1 in breast cancer. JAKSTAT (2013) 1.00
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer (2015) 0.94
STAT signaling in different breast cancer sub-types. Mol Cell Endocrinol (2013) 0.83
Transcriptional regulation of oncogenic protein kinase Cϵ (PKCϵ) by STAT1 and Sp1 proteins. J Biol Chem (2014) 0.81
DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells. Mol Cancer (2014) 0.81
A novel mechanism of skin tumor promotion involving interferon-gamma (IFNγ)/signal transducer and activator of transcription-1 (Stat1) signaling. Mol Carcinog (2014) 0.79
Increased STAT1 signaling in endocrine-resistant breast cancer. PLoS One (2014) 0.78
Role of STAT1 in the breast. JAKSTAT (2012) 0.76
The relationship between total and phosphorylated STAT1 and STAT3 tumour cell expression, components of tumour microenvironment and survival in patients with invasive ductal breast cancer. Oncotarget (2016) 0.75
The transcriptional STAT3 is a potential target, whereas transcriptional STAT5A/5B/6 are new biomarkers for prognosis in human breast carcinoma. Oncotarget (2017) 0.75
Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models. J Steroid Biochem Mol Biol (2017) 0.75
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol (2005) 4.69
Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Hum Pathol (2002) 1.97
Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer (2010) 1.71
Statin treated patients have reduced intraplaque angiogenesis in carotid endarterectomy specimens. Atherosclerosis (2007) 1.60
The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol (2008) 1.59
Actinomycosis of the appendix and pelvis: a case report. J Reprod Med (2008) 1.58
Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Cancer (2008) 1.43
Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res (2008) 1.26
Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncol (2005) 1.12
Embryonal rhabdomyosarcoma of the uterine cervix. Clin Transl Oncol (2009) 1.12
A mixability theory for the role of sex in evolution. Proc Natl Acad Sci U S A (2008) 1.08
Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer (2011) 1.06
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Res Treat (2011) 1.05
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat (2012) 1.01
Application of alpha-smooth muscle actin and c-kit in the differential diagnosis of adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Oral Oncol (2006) 1.01
Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. Ren Fail (2010) 1.00
The expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and angiogenesis markers in hyperplastic and malignant prostate tissue. Anticancer Res (2006) 1.00
Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol (2002) 0.98
Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome. Breast Cancer Res (2006) 0.97
Granulosa cell tumor of the ovary: tumor review. Integr Cancer Ther (2008) 0.96
The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin. Nephrol Dial Transplant (2010) 0.96
Primary aortojejunal fistula due to foreign body: a rare cause of gastrointestinal bleeding. Eur J Gastroenterol Hepatol (2002) 0.94
Stromelysin-3 protein expression in invasive breast cancer: relation to proliferation, cell survival and patients' outcome. Mod Pathol (2002) 0.93
Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. Molecules (2009) 0.93
The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma. Gynecol Oncol (2006) 0.92
Sex, mixability, and modularity. Proc Natl Acad Sci U S A (2010) 0.92
Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid. Transl Res (2010) 0.92
Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma (2003) 0.91
All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev (2010) 0.91
Potential role of the alcohol and smoking in the squamous cell carcinoma of the head and neck: review of the current literature and new perspectives. Asian Pac J Cancer Prev (2011) 0.91
Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev (2011) 0.91
Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology (2011) 0.91
Imaging in situ breast carcinoma (with or without an invasive component) with technetium-99m pentavalent dimercaptosuccinic acid and technetium-99m 2-methoxy isobutyl isonitrile scintimammography. Breast Cancer Res (2004) 0.90
Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas. Histopathology (2010) 0.90
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. Anticancer Res (2011) 0.89
Effect of the different phosphorylated Smad2 protein localizations on the invasive breast carcinoma phenotype. APMIS (2007) 0.89
Adolescents' reactions after a wildfire disaster in Greece. J Trauma Stress (2012) 0.88
Clinicopathologic predictors of death and ESRD in patients with pauci-immune necrotizing glomerulonephritis. Am J Kidney Dis (2003) 0.87
Corticomedullary mixed adrenal tumor: case report and literature review. Endocr J (2009) 0.86
Evaluation of the vascular endothelial growth factor (VEGF)-C role in urothelial carcinomas of the bladder. Anticancer Res (2006) 0.86
Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer (2005) 0.86
Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. Anticancer Res (2007) 0.85
Clinical significance of histone deacetylase (HDAC)-1, HDAC-2, HDAC-4, and HDAC-6 expression in human malignant and benign thyroid lesions. Tumour Biol (2013) 0.85
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat (2005) 0.85
Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer. Mod Pathol (2002) 0.85
Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer. Biomark Insights (2008) 0.85
A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer. Int J Gastrointest Cancer (2005) 0.85
Detection of human papillomavirus (HPV) DNA prevalence and p53 codon 72 (Arg72Pro) polymorphism in prostate cancer in a Greek group of patients. Tumour Biol (2014) 0.84
Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome. J Clin Oncol (2005) 0.84
Basaloid squamous cell carcinoma versus basal cell adenocarcinoma of the oral cavity. Pathology (2005) 0.84
Nuclear hTERT immunohistochemical expression is associated with survival of patients with urothelial bladder cancer. Anticancer Res (2005) 0.83
Cyclin D1 in invasive breast carcinoma: favourable prognostic significance in unselected patients and within subgroups with an aggressive phenotype. Histopathology (2012) 0.83
Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol (2004) 0.83
Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications. Urol Res (2002) 0.82
Immunohistochemical expression of P15 (INK4B) and SMAD4 in advanced gastric cancer. Anticancer Res (2008) 0.82
An immunohistochemical evaluation of the proteins Wnt1 and glycogen synthase kinase (GSK)-3β in invasive breast carcinomas. Histopathology (2013) 0.82
Biopsy-proven resolution of renal light-chain deposition disease after autologous stem cell transplantation. Nephrol Dial Transplant (2010) 0.82
Evaluation of numeric alterations of chromosomes 1 and 17 by in situ hybridization in invasive breast carcinoma with clinicopathologic parameters. Appl Immunohistochem Mol Morphol (2002) 0.82
Immunohistochemical detection of the expression of the cell adhesion molecules E-cadherin, desmoglein-2, beta4-integrin, ICAM-1 and HCAM (CD44s) in Warthin's tumour of the parotid gland. Oral Oncol (2005) 0.81
Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. PLoS One (2013) 0.81
Short- versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: a meta-analysis of randomized controlled trials. Clin Ther (2008) 0.81
Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas. Clin Cancer Res (2003) 0.81
Extra copies of chromosomes 16 and X in invasive breast carcinomas are related to aggressive phenotype and poor prognosis. J Clin Pathol (2007) 0.80
Local treatment of experimental Pseudomonas aeruginosa osteomyelitis with a biodegradable dilactide polymer releasing ciprofloxacin. Antimicrob Agents Chemother (2008) 0.80
Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience. Oncology (2006) 0.80
Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. PLoS One (2013) 0.80
IMAC fractionation in combination with LC-MS reveals H2B and NIF-1 peptides as potential bladder cancer biomarkers. J Proteome Res (2013) 0.80
The key role of bisphosphonates in the supportive care of cancer patients. Anticancer Res (2014) 0.80
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. Breast Cancer Res Treat (2014) 0.80
Differential effect of the expression of TGF-β pathway inhibitors, Smad-7 and Ski, on invasive breast carcinomas: relation to biologic behavior. APMIS (2011) 0.80
Aneuploidy of chromosome 20 in invasive breast cancer correlates with poor outcome. Cancer Genet Cytogenet (2002) 0.79
Serum lipid profile and hepatic steatosis of adult beta-thalassaemia patients with chronic HCV infection. Eur J Gastroenterol Hepatol (2005) 0.79
Evaluation of E-cadherin/catenin complex in primary and secondary glomerulonephritis. Am J Kidney Dis (2002) 0.79
High dose therapy with autologous stem cell transplantation for solitary bone plasmacytoma complicated by local relapse or isolated distant recurrence. Leuk Lymphoma (2003) 0.78
Rapamycin induced ultrastructural and molecular alterations in glomerular podocytes in healthy mice. Nephrol Dial Transplant (2012) 0.78
Immunohistochemical evaluation of phosphorylated SMAD2/SMAD3 and the co-activator P300 in human glomerulonephritis: correlation with renal injury. J Cell Mol Med (2006) 0.77